ReviewJournal of diabetes and metabolic disorders2026
Timing matters: a life-course review of midlife type 2 diabetes, exposure duration, and late-life dementia risk.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This review synthesizes the evidence regarding Type 2 diabetes mellitus (T2DM) as a critical modifiable risk factor for dementia through a life-course lens. The primary purpose is to move beyond the general association and determine how the timing and severity of T2DM, specifically age at onset, duration of disease, and glycemic instability, influence cognitive decline. Consequently, this paper seeks to answer the central research question: How do midlife versus late-life T2DM onset and cumulative glycemic exposure independently contribute to the long-term risk and biological pathways of late-life dementia? Methods: A structured narrative review was conducted using predefined search strategies and study selection criteria, focusing on peer-reviewed studies published 2020-2025 and key longitudinal cohorts. Studies included large prospective cohorts, population-based analyses, or meta-analyses reporting hazard ratios (HRs), relative risks (RRs), or odds ratios (ORs) for incident dementia, Alzheimer's disease (AD), or vascular dementia (VaD). Key exposures included midlife onset, duration, cumulative glycemic measures, and severe hypoglycemia. Results: T2DM was associated with a 1.3-1.8-fold increased risk of incident dementia. Earlier onset and longer duration showed graded risk increases, while higher cumulative glycemic burden and severe hypoglycemia were linked to greater dementia incidence. Associations were stronger for VaD than AD. Conclusions: Midlife T2DM appears to be a strong exposure-dependent risk factor for late-life dementia. Preventing T2DM onset, maintaining stable glycemic control, and minimizing hypoglycemia may be associated with lower future dementia risk, pending confirmation in interventional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.